Bortezomib, thalidomide, and dexamethasone versus thalidomide and dexamethasone for response rates in multiple myeloma patients: a retrospective study
Introduction: The most current treatment of multiple myeloma is based on a combination of drugs, including immunomodulators and proteasome inhibitors. The bortezomib, thalidomide, and dexamethasone (VTD) and thalidomide and dexamethasone (TD) regimens are commonly used as a first-line treatment due...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Permanyer
2025-01-01
|
| Series: | Revista Médica del Hospital General de México |
| Subjects: | |
| Online Access: | https://www.hospitalgeneral.mx/frame_eng.php?id=240 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1825200109922549760 |
|---|---|
| author | Juan M. Cano-Calderón Juan F. Zazueta-Pozos Adán G. Gallardo-Rodríguez Carlos Martínez-Murillo Irma Olarte-Carrillo Adolfo Martínez-Tovar Christian O. Ramos-Peñafiel |
| author_facet | Juan M. Cano-Calderón Juan F. Zazueta-Pozos Adán G. Gallardo-Rodríguez Carlos Martínez-Murillo Irma Olarte-Carrillo Adolfo Martínez-Tovar Christian O. Ramos-Peñafiel |
| author_sort | Juan M. Cano-Calderón |
| collection | DOAJ |
| description | Introduction: The most current treatment of multiple myeloma is based on a combination of drugs, including immunomodulators and proteasome inhibitors. The bortezomib, thalidomide, and dexamethasone (VTD) and thalidomide and dexamethasone (TD) regimens are commonly used as a first-line treatment due to limited resources. Objective: To compare the proportion of favorable responses, survival, and time to the next treatment between two different treatment approaches. Materials and methods: Retrospective study based on medical records of patients with multiple myeloma, eligible for stem cell transplantation, who received, first-line, the VTD or TD combination. Results: A total of 83 patients were analyzed. The average age was 57 years. The most common type of MM was immunoglobulin G kappa (79.5%), and 51.8% had an International Staging System score of 3. At diagnosis, 28.9% had renal failure, and 42.2% had albumin levels < 3 g/dL. 37.3% were treated with the TD regimen, whereas 62.7% received the VTD regimen. It was considered that 53% had a favorable response. However, patients treated with ETV showed a higher proportion of responses (54.8% vs. 39.3%, p = 0.011). Regarding survival, no differences were identified between the two treatments (Log Rank 0.076) or between the times until the next treatment (Log Rank 0.288). Conclusion: The VTD scheme was superior to the TD scheme, presenting response ratios similar to other series worldwide. This makes it a viable option for patients with limited financial resources.
|
| format | Article |
| id | doaj-art-9ab1bdf08314496d8099ce08b39f689e |
| institution | Kabale University |
| issn | 0185-1063 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Permanyer |
| record_format | Article |
| series | Revista Médica del Hospital General de México |
| spelling | doaj-art-9ab1bdf08314496d8099ce08b39f689e2025-02-07T20:39:16ZengPermanyerRevista Médica del Hospital General de México0185-10632025-01-01881Bortezomib, thalidomide, and dexamethasone versus thalidomide and dexamethasone for response rates in multiple myeloma patients: a retrospective studyJuan M. Cano-Calderón0Juan F. Zazueta-Pozos1Adán G. Gallardo-Rodríguez2Carlos Martínez-Murillo3Irma Olarte-Carrillo4Adolfo Martínez-Tovar5Christian O. Ramos-Peñafiel6Department of Hematology, Hospital General de México Dr. Eduardo Liceaga, Mexico City, MexicoDepartment of Hematology, Hospital General de México Dr. Eduardo Liceaga, Mexico City, MexicoDepartment of Hematology, Hospital General de México Dr. Eduardo Liceaga, Mexico City, MexicoDepartment of Hematology, Hospital General de México Dr. Eduardo Liceaga, Mexico City, MexicoMolecular Biology Laboratory, Department of Hematology, Hospital General de México Dr. Eduardo Liceaga, Mexico City, MexicoMolecular Biology Laboratory, Hospital General de México “Dr. Eduardo Liceaga”; Hematology Service, Hospital General de México “Dr. Eduardo Liceaga”; Mexico City, MexicoMolecular Biology Laboratory, Department of Hematology, Hospital General de México Dr. Eduardo Liceaga, Mexico City, MexicoDepartment of Hematology, Hospital General de México Dr. Eduardo Liceaga, Mexico City, MexicoIntroduction: The most current treatment of multiple myeloma is based on a combination of drugs, including immunomodulators and proteasome inhibitors. The bortezomib, thalidomide, and dexamethasone (VTD) and thalidomide and dexamethasone (TD) regimens are commonly used as a first-line treatment due to limited resources. Objective: To compare the proportion of favorable responses, survival, and time to the next treatment between two different treatment approaches. Materials and methods: Retrospective study based on medical records of patients with multiple myeloma, eligible for stem cell transplantation, who received, first-line, the VTD or TD combination. Results: A total of 83 patients were analyzed. The average age was 57 years. The most common type of MM was immunoglobulin G kappa (79.5%), and 51.8% had an International Staging System score of 3. At diagnosis, 28.9% had renal failure, and 42.2% had albumin levels < 3 g/dL. 37.3% were treated with the TD regimen, whereas 62.7% received the VTD regimen. It was considered that 53% had a favorable response. However, patients treated with ETV showed a higher proportion of responses (54.8% vs. 39.3%, p = 0.011). Regarding survival, no differences were identified between the two treatments (Log Rank 0.076) or between the times until the next treatment (Log Rank 0.288). Conclusion: The VTD scheme was superior to the TD scheme, presenting response ratios similar to other series worldwide. This makes it a viable option for patients with limited financial resources. https://www.hospitalgeneral.mx/frame_eng.php?id=240Multiple myeloma. Bortezomib. Thalidomide. Acute phase response. Survival. |
| spellingShingle | Juan M. Cano-Calderón Juan F. Zazueta-Pozos Adán G. Gallardo-Rodríguez Carlos Martínez-Murillo Irma Olarte-Carrillo Adolfo Martínez-Tovar Christian O. Ramos-Peñafiel Bortezomib, thalidomide, and dexamethasone versus thalidomide and dexamethasone for response rates in multiple myeloma patients: a retrospective study Revista Médica del Hospital General de México Multiple myeloma. Bortezomib. Thalidomide. Acute phase response. Survival. |
| title | Bortezomib, thalidomide, and dexamethasone versus thalidomide and dexamethasone for response rates in multiple myeloma patients: a retrospective study |
| title_full | Bortezomib, thalidomide, and dexamethasone versus thalidomide and dexamethasone for response rates in multiple myeloma patients: a retrospective study |
| title_fullStr | Bortezomib, thalidomide, and dexamethasone versus thalidomide and dexamethasone for response rates in multiple myeloma patients: a retrospective study |
| title_full_unstemmed | Bortezomib, thalidomide, and dexamethasone versus thalidomide and dexamethasone for response rates in multiple myeloma patients: a retrospective study |
| title_short | Bortezomib, thalidomide, and dexamethasone versus thalidomide and dexamethasone for response rates in multiple myeloma patients: a retrospective study |
| title_sort | bortezomib thalidomide and dexamethasone versus thalidomide and dexamethasone for response rates in multiple myeloma patients a retrospective study |
| topic | Multiple myeloma. Bortezomib. Thalidomide. Acute phase response. Survival. |
| url | https://www.hospitalgeneral.mx/frame_eng.php?id=240 |
| work_keys_str_mv | AT juanmcanocalderon bortezomibthalidomideanddexamethasoneversusthalidomideanddexamethasoneforresponseratesinmultiplemyelomapatientsaretrospectivestudy AT juanfzazuetapozos bortezomibthalidomideanddexamethasoneversusthalidomideanddexamethasoneforresponseratesinmultiplemyelomapatientsaretrospectivestudy AT adanggallardorodriguez bortezomibthalidomideanddexamethasoneversusthalidomideanddexamethasoneforresponseratesinmultiplemyelomapatientsaretrospectivestudy AT carlosmartinezmurillo bortezomibthalidomideanddexamethasoneversusthalidomideanddexamethasoneforresponseratesinmultiplemyelomapatientsaretrospectivestudy AT irmaolartecarrillo bortezomibthalidomideanddexamethasoneversusthalidomideanddexamethasoneforresponseratesinmultiplemyelomapatientsaretrospectivestudy AT adolfomartineztovar bortezomibthalidomideanddexamethasoneversusthalidomideanddexamethasoneforresponseratesinmultiplemyelomapatientsaretrospectivestudy AT christianoramospenafiel bortezomibthalidomideanddexamethasoneversusthalidomideanddexamethasoneforresponseratesinmultiplemyelomapatientsaretrospectivestudy |